Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BalanceD-CKD phase 3 study of balcinrenone + dapagliflozin versus dapagliflozin in chronic kidney disease
CTR20263510Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of balcinrenone, dapagliflozin in chronic kidney disease (CKD), sponsored by AstraZeneca. Started Sep 2026; status: active.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20263510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263510.